US COVID-19 Community Response Fund

Novartis US Foundation

Suggest an update

Deadline: Rolling

Grant amount: US $100,000 - US $250,000

Fields of work: Health Policy & Advocacy Community Health Education Health Care Access & Delivery Disaster Relief / Humanitarian Aid

Applicant type: Nonprofit

Funding uses: Education / Outreach, Project / Program

Location of project: California, Illinois, Massachusetts, New Jersey, New York Show all

Location of residency: California, Illinois, Massachusetts, New Jersey, New York Show all

View website    Save

About this funder:

Loading...

Overview:

Novartis US Foundation establishes USD $5 million US COVID-19 Community Response Fund

In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic

You can learn more about this opportunity by visiting the funder's website.

Eligibility:

  • Grant requests must fit within the following criteria:
    • Applicants must be verified 501(c)(3) organizations.
    • Priority will be given to efforts focused on geographies where Novartis has a physical presence and where there is an acute need, including, but not limited to, NJ, MA, CA, IL, NC, and NY.
    • Programs must support one or more of the three stated objectives:
      • Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers
      • Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information
      • Creating or enhancing new community health programs specific to the pandemic response
    • Grant request amounts should be in the range of $100,000 and $250,000.

Ineligibility:

  • The following types of requests are not eligible:
    • R&D efforts related to COVID-19

Loading...